Given that blood anti-NMDAR1 autoantibodies suppress glutamate excitotoxicity in animal models of stroke and epilepsy (During et al., 2000), it is plausible that plasma natural anti-NMDAR1 autoantibodies may ameliorate glutamate excitotoxicity in brain during AD development. This evidence concerns the gene GRIN1 and stroke disorder.